BRPI0716319A8 - método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano correndo o risco de desenvolver ou que desenvolveu hiperfosfatomia e método para reduzir os efeitos colaterais da terapia de vitamina d em um ser humano - Google Patents

método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano correndo o risco de desenvolver ou que desenvolveu hiperfosfatomia e método para reduzir os efeitos colaterais da terapia de vitamina d em um ser humano Download PDF

Info

Publication number
BRPI0716319A8
BRPI0716319A8 BRPI0716319A BRPI0716319A BRPI0716319A8 BR PI0716319 A8 BRPI0716319 A8 BR PI0716319A8 BR PI0716319 A BRPI0716319 A BR PI0716319A BR PI0716319 A BRPI0716319 A BR PI0716319A BR PI0716319 A8 BRPI0716319 A8 BR PI0716319A8
Authority
BR
Brazil
Prior art keywords
human
developing
reducing
hyperphosphatomy
risk
Prior art date
Application number
BRPI0716319A
Other languages
English (en)
Inventor
Helvig Christian
Hellestad Erica
Crawford Keith
Cook Mark
Petrovich Martin
Original Assignee
Aovatechnologies Inc
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aovatechnologies Inc, Wisconsin Alumni Res Found filed Critical Aovatechnologies Inc
Publication of BRPI0716319A2 publication Critical patent/BRPI0716319A2/pt
Publication of BRPI0716319A8 publication Critical patent/BRPI0716319A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

método para reduzir a absorção de fosfato em um indivíduo animal humano ou não - humano correndo o risco de desenvlover ou que desenvolveu hiperfosfatomia e método para reduzir os efeitos colaterais da terapia de vitamina d em um ser humano. trata-se de um método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano correndo o risco de desenvolver ou que desenvolveu hiperfosfatomia. o método inclui a etapa de administração oral ao indivíduo de um anticorpo cotransportador de fosfato de sódio anti-intestinal do tipo 2b (npt 2b) em uma quantidade eficaz para reduzir ou manter a concentração de fosfato de soro no indivíduo.
BRPI0716319A 2006-10-25 2007-10-23 método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano correndo o risco de desenvolver ou que desenvolveu hiperfosfatomia e método para reduzir os efeitos colaterais da terapia de vitamina d em um ser humano BRPI0716319A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86287606P 2006-10-25 2006-10-25
US60/862,876 2006-10-25
PCT/US2007/082247 WO2008051980A2 (en) 2006-10-25 2007-10-23 Methods of reducing phosphate absorption

Publications (2)

Publication Number Publication Date
BRPI0716319A2 BRPI0716319A2 (pt) 2013-02-13
BRPI0716319A8 true BRPI0716319A8 (pt) 2019-02-05

Family

ID=39205304

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0716319A BRPI0716319A8 (pt) 2006-10-25 2007-10-23 método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano correndo o risco de desenvolver ou que desenvolveu hiperfosfatomia e método para reduzir os efeitos colaterais da terapia de vitamina d em um ser humano

Country Status (9)

Country Link
US (1) US8802094B2 (pt)
EP (1) EP2076286B1 (pt)
JP (1) JP5535638B2 (pt)
CN (1) CN101568349B (pt)
AU (1) AU2007309029B2 (pt)
BR (1) BRPI0716319A8 (pt)
CA (1) CA2667524C (pt)
ES (1) ES2573636T3 (pt)
WO (1) WO2008051980A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010508281A (ja) 2006-10-26 2010-03-18 ウィスコンシン・アラムナイ・リサーチ・ファウンデイション リン酸塩吸収の低減方法
PE20121584A1 (es) 2009-11-30 2012-11-29 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores
BR112018068461A2 (pt) 2016-03-15 2019-01-22 Mersana Therapeutics Inc conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
KR20200055770A (ko) 2017-09-20 2020-05-21 메르사나 테라퓨틱스, 인코포레이티드 Napi2b 표적 요법에 대한 반응을 예측하기 위한 조성물 및 방법
TW202035452A (zh) 2018-08-17 2020-10-01 美商梅爾莎納醫療公司 靶向ＮａＰｉ２ｂ之聚合物抗體－藥物共軛體和使用彼之方法
WO2023219127A1 (ja) 2022-05-11 2023-11-16 中外製薬株式会社 嚢胞性疾患を治療または予防するための医薬組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH0225254H1 (en) 1985-11-25 1998-09-15 Ghen Corp Specific antibody-containing substance from eggs and method of production and use thereof
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
AU1526995A (en) 1994-01-13 1995-08-01 Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations, The Antibodies specific for d-myo-inositol 1,4,5-trisphosphate
KR100406912B1 (ko) 1994-08-05 2004-02-18 위스콘신 얼럼나이 리서어치 화운데이션 사료효율을향상시키기위하여사용되는cck항체
US5597815A (en) * 1995-07-13 1997-01-28 Wisconsin Alumni Research Foundation Prevention of hyperphosphatemia in kidney disorder patients
ES2162658T3 (es) 1996-03-05 2002-01-01 Mitsubishi Chem Corp Utilizacion de resinas intercambiadoras anionicas para la fabricacion de un medicamento destinado al tratamiento de la hiperfosfatemia.
KR20000067929A (ko) 1996-07-19 2000-11-25 나가타 코이치 고인혈증 치료제
AU729502B2 (en) * 1996-10-02 2001-02-01 Ovimmune, Inc. Oral administration of chicken yolk antibodies to treat disease
US6423754B1 (en) 1997-06-18 2002-07-23 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with polyallylamine polymers
US5985938A (en) 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
CH694588A5 (de) 1999-02-09 2005-04-15 Hoffmann La Roche Menschliche intestinale Npt2B.
US6213930B1 (en) 1999-03-15 2001-04-10 Wisconsin Alumni Research Foundation Method of using anti-phospholipase A2 antibodies to enhance growth or improve feed efficiency
EP1246848A1 (en) 1999-12-27 2002-10-09 University Of Manitoba GENETIC VACCINES FOR THE PRODUCTION OF CHICKEN EGG-YOLK ANTIBODIES AGAINST ENTEROTOXIGENIC i ESCHERICHIA COLI /i AND OTHER PATHOGENS
AU2001271880A1 (en) 2000-07-06 2002-01-21 Deltagen, Inc. Transgenic mice containing targeted phosphatase gene disruptions
WO2005099753A1 (en) * 2004-04-16 2005-10-27 The Govenors Of The University Of Alberta Anti-gluten egg yolk antibodies for the treatment of celiac disease
JP2010508281A (ja) 2006-10-26 2010-03-18 ウィスコンシン・アラムナイ・リサーチ・ファウンデイション リン酸塩吸収の低減方法

Also Published As

Publication number Publication date
CA2667524C (en) 2017-02-07
JP2010508283A (ja) 2010-03-18
EP2076286A2 (en) 2009-07-08
CN101568349A (zh) 2009-10-28
WO2008051980A8 (en) 2009-05-28
JP5535638B2 (ja) 2014-07-02
ES2573636T3 (es) 2016-06-09
CA2667524A1 (en) 2008-05-02
AU2007309029A1 (en) 2008-05-02
CN101568349B (zh) 2012-09-19
WO2008051980A2 (en) 2008-05-02
BRPI0716319A2 (pt) 2013-02-13
AU2007309029B2 (en) 2013-05-09
WO2008051980A3 (en) 2008-06-19
US20100166760A1 (en) 2010-07-01
US8802094B2 (en) 2014-08-12
EP2076286B1 (en) 2016-03-09

Similar Documents

Publication Publication Date Title
Valvassori et al. Lithium ameliorates sleep deprivation‐induced mania‐like behavior, hypothalamic‐pituitary‐adrenal (HPA) axis alterations, oxidative stress and elevations of cytokine concentrations in the brain and serum of mice
Kaye et al. Folic acid supplementation in patients with elevated homocysteine levels
CA3118834C (en) Resetting biological pathways for defending against and repairing deterioration from human aging
Nimni et al. Are we getting enough sulfur in our diet?
Hoffer et al. Sulfate could mediate the therapeutic effect of glucosamine sulfate
Bertolo et al. The nutritional burden of methylation reactions
BRPI0716317A8 (pt) método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano e método para reduzir a absorção de fosfato em um indivíduo humano
Green Vitamin B12 deficiency from the perspective of a practicing hematologist
Li et al. Dehydroepiandrosterone protects against hepatic glycolipid metabolic disorder and insulin resistance induced by high fat via activation of AMPK-PGC-1α-NRF-1 and IRS1-AKT-GLUT2 signaling pathways
Trumble The use of nutraceuticals for osteoarthritis in horses
Yun et al. Plasma homocysteine level and hepatic sulfur amino acid metabolism in mice fed a high-fat diet
BRPI0519391A2 (pt) mÉtodo para promover a saéde oral em um animal, kit adequado para administraÇço de um ou mais antioxidantes a um animal, dispositivo para transmitir informaÇço ou instruÇÕes, e, uso de uma composiÇço
BR112014010228A2 (pt) inibidores de reciclagem de ácidos biliares para tratamento da doença de fígado e hipercolemia colestática
Herrera et al. Toxic effects of perinatal arsenic exposure on the brain of developing rats and the beneficial role of natural antioxidants
Hoenjet et al. Effect of a nutritional supplement containing vitamin E, selenium, vitamin C and coenzyme Q10 on serum PSA in patients with hormonally untreated carcinoma of the prostate: a randomised placebo-controlled study
Zarazúa et al. Decreased nitric oxide production in the rat brain after chronic arsenic exposure
BR112014008512A2 (pt) composições nutricionais de caseína-soro de leite parcialmente hidrolizadas para redução do início de alergias
Donati et al. Effects of aging, antiaging calorie restriction and in vivo stimulation of autophagy on the urinary excretion of 8OHdG in male Sprague–Dawley rats
Tesone‐Coelho et al. Vulnerability to opiate intake in maternally deprived rats: implication of MeCP 2 and of histone acetylation
Mušinović et al. β‐Carotene during the suckling period is absorbed intact and induces retinoic acid dependent responses similar to preformed vitamin A in intestine and liver, but not adipose tissue of young rats
WO2008051980A3 (en) Methods of reducing phosphate absorption
de Moraes Ramos et al. Evaluation of radioprotective effect of vitamin E in salivary dysfunction in irradiated rats
Muizzuddin et al. Beneficial effects of a sulfur-containing supplement on hair and nail condition
Huang et al. Pre-gestational stress alters stress-response of pubertal offspring rat in sexually dimorphic and hemispherically asymmetric manner
August et al. Effect of maternal antioxidant supplementation and/or exercise practice during pregnancy on postnatal overnutrition induced by litter size reduction: Brain redox homeostasis at weaning

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]